Evidence map›Paper›PMID 32273347›Full record

ArticleJournal for immunotherapy of cancer2020

Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103

Yifan Zhou, Natalie Slone, Taylor T Chrisikos, Oleksandr Kyrysyuk, Rachel L Babcock, Yusra B Medik, Haiyan S Li, Eugenie S Kleinerman, Stephanie S Watowich

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yifan ZhouImmunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Natalie SloneImmunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Taylor T ChrisikosImmunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Oleksandr KyrysyukImmunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rachel L BabcockImmunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yusra B MedikImmunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Haiyan S LiImmunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Eugenie S KleinermanImmunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Stephanie S WatowichImmunology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA swatowic@mdanderson.org.ORCID 0000-0003-1969-659X
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Regulation and function of nonlymphoid organ CD103 dendritic cellsR01AI109294 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WATOWICH, STEPHANIE S · 2015 to 2019
$2.0M
Regulation and function of nonlymphoid organ CD103+ dendritic cellsR56AI109294 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI WATOWICH, STEPHANIE S · 2021 to 2021
$481k
NCI NIH HHS P30 CA016672NIAID NIH HHS R01 AI109294NIAID NIH HHS R56 AI109294
6 · The paper itself

Abstract

backgroundType 1 conventional dendritic cells (cDC1s) possess efficient antigen presentation and cross-presentation activity, as well as potent T cell priming ability. Tissue-resident cDC1s (CD103

methodsWe generated murine CD103

resultsIn vitro-generated CD103

conclusionsOur data indicate an in vitro-generated CD103

Indexed as

AnimalsAntigen PresentationAntigens, CDAntigens, NeoplasmBone NeoplasmsCross-PrimingDendritic CellsImmunotherapyIntegrin alpha ChainsIn Vitro TechniquesLung NeoplasmsMelanoma, ExperimentalMiceMice, Inbred C57BLOsteosarcomaSarcoma, Experimentalalpha E integrinsAntigens, CDAntigens, NeoplasmIntegrin alpha ChainsVaccinesCD103+dendritic cell vaccineimmune checkpoint blockademelanomaosteosarcoma

Identifiers

PMID32273347
PMCPMC7254126
OpenAlexW3015270738

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.